Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.36 |
| ▸ | PPARA | Q07869 | 9/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | LSS | P48449 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379771 | 0.90 | PPARD (0.39) | PPARGPPARA | |
| SCHEMBL3379726 | 0.90 | PPARD (0.39) | PPARGPPARA | |
| SCHEMBL3378319 | 0.90 | PPARA (0.39) | PPARGPPARA | |
| SCHEMBL13069525 | 0.88 | PPARD (0.35) | PPARGPPARA | |
| SCHEMBL3376909 | 0.77 | PPARD (0.53) | PPARGPPARA | |
| SCHEMBL3376978 | 0.77 | PPARD (0.53) | PPARGPPARA | |
| SCHEMBL3379734 | 0.77 | PPARD (0.37) | PPARGPPARAMAPTESR1ESR2 | |
| SCHEMBL3376972 | 0.77 | PPARD (0.37) | PPARGPPARAMAPTESR1ESR2 | |
| SCHEMBL4382214 | 0.67 | CYP3A4 (0.41) | PPARGPPARAMAPTPTGS2ATM | |
| SCHEMBL3378769 | 0.67 | PPARA (0.43) | PPARAMAPTESR1ESR2LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | PPARG 152/4885PPARA 111/4885MAPT 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.